Literature DB >> 1834698

Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.

M Volpe1, C Tritto, N De Luca, A F Mele, G Lembo, S Rubattu, M Romano, P De Campora, I Enea, B Ricciardelli.   

Abstract

To investigate whether the response of atrial natriuretic factor (ANF) to volume expansion is impaired in the early stages of dilated cardiomyopathy, the effects of saline load (SL; 0.25 ml/kg.min for 120 min) were assessed in 12 patients with dilated cardiomyopathy and asymptomatic to mildly symptomatic heart failure (HF) and in nine normal subjects (N). SL increased plasma ANF levels in N (from 14.3 +/- 2 to 19.5 +/- 3 and 26 +/- 4 pg/ml, at 60 and 120 min, respectively, P less than 0.001), but not in HF (from 42.9 +/- 9 to 45.9 +/- 9 and 43.9 +/- 8 pg/ml). Left ventricular end-diastolic volume (LVEDV) and stroke volume were increased (P less than 0.001) by SL in N but not in HF. Urinary sodium excretion (UNaV) increased in N more than in HF during SL, whereas forearm vascular resistance (FVR) did not change in N and increased in HF (P less than 0.001). In five HF patients SL was performed during ANF infusion (50 ng/kg, 5 ng/kg.min) that increased ANF levels from 37.1 +/- 10 to 146 +/- 22 pg/ml. In this group, SL raised both LVEDV (P less than 0.01) and ANF (P less than 0.05), whereas FVR did not rise. In addition, the UNaV increase and renin and aldosterone suppressions by SL were more marked than those observed in HF under control conditions. Thus, in patients with dilated cardiomyopathy and mild cardiac dysfunction, plasma ANF levels are not increased by volume expansion as observed in N. The lack of ANF response is related to the impaired cardiac adaptations. The absence of an adequate increase of ANF levels may contribute to the abnormal responses of HF patients to saline load.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1834698      PMCID: PMC295653          DOI: 10.1172/JCI115458

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1962-12       Impact factor: 4.030

2.  [Diagnosis of ischemic cardiopathy in hypertensive patients. Comparison of radioisotopic technics].

Authors:  A Cuocolo; S Esposito; C Acampora; G Squame
Journal:  Radiol Med       Date:  1988-03       Impact factor: 3.469

3.  Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure.

Authors:  B S Edwards; D M Ackermann; M E Lee; G S Reeder; L E Wold; J C Burnett
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

4.  Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat.

Authors:  J E Greenwald; M Sakata; M L Michener; S D Sides; P Needleman
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

5.  Increased ANF secretion after volume expansion is preserved in rats with heart failure.

Authors:  Y W Chien; R W Barbee; A A MacPhee; E D Frohlich; N C Trippodo
Journal:  Am J Physiol       Date:  1988-02

6.  Atrial natriuretic factor potentiates forearm reflex vasoconstriction induced by cardiopulmonary receptor deactivation in man.

Authors:  M Volpe; N De Luca; M C Bigazzi; F Vecchione; G Lembo; M Condorelli; B Trimarco
Journal:  Circulation       Date:  1988-04       Impact factor: 29.690

7.  Atrial natriuretic peptide transcription, storage, and release in rats with myocardial infarction.

Authors:  R E Mendez; J M Pfeffer; F V Ortola; K D Bloch; S Anderson; J G Seidman; B M Brenner
Journal:  Am J Physiol       Date:  1987-12

8.  Vasodilatory actions of alpha-human atrial natriuretic peptide and high Ca2+ effects in normal man.

Authors:  T Fujita; Y Ito; H Noda; Y Sato; K Ando; K Kangawa; H Matsuo
Journal:  J Clin Invest       Date:  1987-09       Impact factor: 14.808

9.  Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy volunteers.

Authors:  I Tikkanen; F Fyhrquist; K Metsärinne; R Leidenius
Journal:  Lancet       Date:  1985-07-13       Impact factor: 79.321

10.  Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Role of changes in heart rate, atrial dimension, and cardiac tissue concentration.

Authors:  G W Moe; E A Grima; C Angus; N L Wong; D C Hu; R J Howard; P W Armstrong
Journal:  Circulation       Date:  1991-05       Impact factor: 29.690

View more
  12 in total

Review 1.  Soluble guanylate cyclase modulators in heart failure.

Authors:  Veselin Mitrovic; Ana Jovanovic; Stefan Lehinant
Journal:  Curr Heart Fail Rep       Date:  2011-03

2.  AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart failure and acute respiratory failure.

Authors:  S Savastano; V Cannavale; R Valentino; A P Tommaselli; R Rossi; A Luciano; L Tauchmanovà; A Mariano; L Mazzitelli; V Macchia; G Lombardi
Journal:  J Endocrinol Invest       Date:  1999-11       Impact factor: 4.256

3.  Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.

Authors:  Noel S Lee; Lori B Daniels
Journal:  Card Fail Rev       Date:  2016-05

4.  Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction.

Authors:  Paul M McKie; John A Schirger; Lisa C Costello-Boerrigter; Sherry L Benike; Lynn K Harstad; Kent R Bailey; David O Hodge; Margaret M Redfield; Robert D Simari; John C Burnett; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

Review 5.  NPR-C: a component of the natriuretic peptide family with implications in human diseases.

Authors:  Speranza Rubattu; Sebastiano Sciarretta; Angelica Morriello; Camilla Calvieri; Allegra Battistoni; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2010-06-19       Impact factor: 4.599

6.  Vasopressin release during orthostatic hypotension after cardiac transplantation.

Authors:  S W Lord; S Brady; P H Baylis; J H Dark; R A Kenny; J M McComb
Journal:  Clin Auton Res       Date:  1996-12       Impact factor: 4.435

7.  Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure.

Authors:  Paul M McKie; John A Schirger; Sherry L Benike; Lynn K Harstad; Joshua P Slusser; David O Hodge; Margaret M Redfield; John C Burnett; Horng H Chen
Journal:  Eur J Heart Fail       Date:  2016-01-24       Impact factor: 15.534

8.  A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.

Authors:  T L Stevens; J C Burnett; M Kinoshita; Y Matsuda; M M Redfield
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

Review 9.  Mechanisms and Models in Heart Failure: A Translational Approach.

Authors:  Douglas L Mann; G Michael Felker
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

Review 10.  Natriuretic peptides in the pathophysiology of congestive heart failure.

Authors:  H H Chen; J C Burnett
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 3.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.